vs

Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and INNODATA INC (INOD). Click either name above to swap in a different company.

INNODATA INC is the larger business by last-quarter revenue ($72.4M vs $62.1M, roughly 1.2× Cytek Biosciences, Inc.). INNODATA INC runs the higher net margin — 12.2% vs -70.9%, a 83.1% gap on every dollar of revenue. On growth, INNODATA INC posted the faster year-over-year revenue change (22.3% vs 8.1%). INNODATA INC produced more free cash flow last quarter ($10.1M vs $-1.8M). Over the past eight quarters, INNODATA INC's revenue compounded faster (65.3% CAGR vs 17.7%).

Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.

Innodata Inc., formerly Innodata Isogen, Inc., is an American company that provides business process, technology and consulting services. The company also provides products that aim to help clients create, manage, use and distribute digital information.

CTKB vs INOD — Head-to-Head

Bigger by revenue
INOD
INOD
1.2× larger
INOD
$72.4M
$62.1M
CTKB
Growing faster (revenue YoY)
INOD
INOD
+14.2% gap
INOD
22.3%
8.1%
CTKB
Higher net margin
INOD
INOD
83.1% more per $
INOD
12.2%
-70.9%
CTKB
More free cash flow
INOD
INOD
$11.8M more FCF
INOD
$10.1M
$-1.8M
CTKB
Faster 2-yr revenue CAGR
INOD
INOD
Annualised
INOD
65.3%
17.7%
CTKB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CTKB
CTKB
INOD
INOD
Revenue
$62.1M
$72.4M
Net Profit
$-44.1M
$8.8M
Gross Margin
52.9%
38.3%
Operating Margin
-9.0%
15.1%
Net Margin
-70.9%
12.2%
Revenue YoY
8.1%
22.3%
Net Profit YoY
-557.1%
-14.2%
EPS (diluted)
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTKB
CTKB
INOD
INOD
Q4 25
$62.1M
$72.4M
Q3 25
$52.3M
$62.5M
Q2 25
$45.6M
$58.4M
Q1 25
$41.5M
$58.3M
Q4 24
$57.5M
$59.2M
Q3 24
$51.5M
$52.2M
Q2 24
$46.6M
$32.6M
Q1 24
$44.9M
$26.5M
Net Profit
CTKB
CTKB
INOD
INOD
Q4 25
$-44.1M
$8.8M
Q3 25
$-5.5M
$8.3M
Q2 25
$-5.6M
$7.2M
Q1 25
$-11.4M
$7.8M
Q4 24
$9.6M
$10.3M
Q3 24
$941.0K
$17.4M
Q2 24
$-10.4M
$-14.0K
Q1 24
$-6.2M
$989.0K
Gross Margin
CTKB
CTKB
INOD
INOD
Q4 25
52.9%
38.3%
Q3 25
52.7%
40.8%
Q2 25
52.3%
39.4%
Q1 25
48.6%
39.9%
Q4 24
58.5%
45.2%
Q3 24
56.3%
40.8%
Q2 24
54.6%
28.7%
Q1 24
51.3%
36.4%
Operating Margin
CTKB
CTKB
INOD
INOD
Q4 25
-9.0%
15.1%
Q3 25
-17.6%
18.8%
Q2 25
-23.3%
15.3%
Q1 25
-36.1%
14.2%
Q4 24
5.2%
19.0%
Q3 24
-8.2%
21.9%
Q2 24
-18.3%
1.0%
Q1 24
-23.9%
5.0%
Net Margin
CTKB
CTKB
INOD
INOD
Q4 25
-70.9%
12.2%
Q3 25
-10.5%
13.3%
Q2 25
-12.2%
12.4%
Q1 25
-27.5%
13.3%
Q4 24
16.8%
17.4%
Q3 24
1.8%
33.3%
Q2 24
-22.4%
-0.0%
Q1 24
-13.8%
3.7%
EPS (diluted)
CTKB
CTKB
INOD
INOD
Q4 25
$0.26
Q3 25
$0.24
Q2 25
$0.20
Q1 25
$0.22
Q4 24
$0.35
Q3 24
$0.51
Q2 24
$0.00
Q1 24
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTKB
CTKB
INOD
INOD
Cash + ST InvestmentsLiquidity on hand
$90.9M
$82.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$341.7M
$107.1M
Total Assets
$461.5M
$168.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTKB
CTKB
INOD
INOD
Q4 25
$90.9M
$82.2M
Q3 25
$93.3M
$73.9M
Q2 25
$75.5M
$59.8M
Q1 25
$95.3M
$56.6M
Q4 24
$98.7M
$46.9M
Q3 24
$162.3M
$26.4M
Q2 24
$177.9M
$16.5M
Q1 24
$168.8M
$19.0M
Stockholders' Equity
CTKB
CTKB
INOD
INOD
Q4 25
$341.7M
$107.1M
Q3 25
$378.6M
$97.3M
Q2 25
$377.6M
$86.7M
Q1 25
$379.6M
$75.5M
Q4 24
$395.7M
$63.5M
Q3 24
$385.5M
$47.7M
Q2 24
$389.1M
$29.0M
Q1 24
$392.6M
$27.6M
Total Assets
CTKB
CTKB
INOD
INOD
Q4 25
$461.5M
$168.6M
Q3 25
$494.9M
$152.9M
Q2 25
$493.3M
$132.6M
Q1 25
$482.6M
$125.2M
Q4 24
$499.5M
$113.4M
Q3 24
$491.2M
$88.2M
Q2 24
$483.7M
$66.0M
Q1 24
$492.1M
$63.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTKB
CTKB
INOD
INOD
Operating Cash FlowLast quarter
$-771.0K
$12.9M
Free Cash FlowOCF − Capex
$-1.8M
$10.1M
FCF MarginFCF / Revenue
-2.9%
13.9%
Capex IntensityCapex / Revenue
1.6%
3.9%
Cash ConversionOCF / Net Profit
1.46×
TTM Free Cash FlowTrailing 4 quarters
$-8.8M
$35.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTKB
CTKB
INOD
INOD
Q4 25
$-771.0K
$12.9M
Q3 25
$-3.9M
$18.8M
Q2 25
$108.0K
$4.2M
Q1 25
$-125.0K
$10.9M
Q4 24
$2.0M
$17.2M
Q3 24
$13.2M
$11.4M
Q2 24
$6.2M
$-454.0K
Q1 24
$4.0M
$6.8M
Free Cash Flow
CTKB
CTKB
INOD
INOD
Q4 25
$-1.8M
$10.1M
Q3 25
$-4.6M
$14.5M
Q2 25
$-1.5M
$2.5M
Q1 25
$-974.0K
$8.5M
Q4 24
$1.1M
$15.0M
Q3 24
$12.2M
$9.9M
Q2 24
$5.2M
$-3.2M
Q1 24
$3.4M
$5.4M
FCF Margin
CTKB
CTKB
INOD
INOD
Q4 25
-2.9%
13.9%
Q3 25
-8.7%
23.2%
Q2 25
-3.2%
4.3%
Q1 25
-2.3%
14.6%
Q4 24
1.9%
25.3%
Q3 24
23.7%
19.0%
Q2 24
11.0%
-9.8%
Q1 24
7.6%
20.5%
Capex Intensity
CTKB
CTKB
INOD
INOD
Q4 25
1.6%
3.9%
Q3 25
1.3%
6.8%
Q2 25
3.5%
2.9%
Q1 25
2.0%
4.0%
Q4 24
1.6%
3.7%
Q3 24
2.0%
2.8%
Q2 24
2.3%
8.4%
Q1 24
1.3%
5.1%
Cash Conversion
CTKB
CTKB
INOD
INOD
Q4 25
1.46×
Q3 25
2.25×
Q2 25
0.59×
Q1 25
1.40×
Q4 24
0.21×
1.67×
Q3 24
14.05×
0.65×
Q2 24
Q1 24
6.84×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTKB
CTKB

Products$46.6M75%
Services$15.5M25%

INOD
INOD

Segment breakdown not available.

Related Comparisons